Investors Buy High Volume of Amneal Pharmaceuticals Call Options (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the target of unusually large options trading on Monday. Stock investors purchased 2,563 call options on the stock. This is an increase of approximately 719% compared to the average daily volume of 313 call options.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AMRX shares. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a report on Friday, September 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 17.46% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in Amneal Pharmaceuticals by 20.7% during the second quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock worth $4,771,000 after acquiring an additional 128,772 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Amneal Pharmaceuticals by 13.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after buying an additional 4,115 shares during the last quarter. Rothschild Investment LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $26,000. nVerses Capital LLC purchased a new position in Amneal Pharmaceuticals during the second quarter valued at $62,000. Finally, Ritholtz Wealth Management boosted its holdings in Amneal Pharmaceuticals by 19.3% in the second quarter. Ritholtz Wealth Management now owns 159,710 shares of the company’s stock worth $1,014,000 after acquiring an additional 25,869 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $7.79 on Tuesday. The company has a 50-day simple moving average of $8.42 and a two-hundred day simple moving average of $7.95. The firm has a market capitalization of $2.41 billion, a PE ratio of -11.46 and a beta of 1.12. Amneal Pharmaceuticals has a one year low of $5.01 and a one year high of $9.48.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.